MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio. ...

2026年1月底， Hologic 豪洛捷 披露截至 2025 年 12 月 27 日的 2026 财年第一季度业绩。 在财报发布节点，公司正处于被黑石与 TPG 私募基金收购的关键阶段，并已明确将于 2026 年 2 月 5 日 召开股东特别大会 ，对并购协议进行表决。 在此背景下，本季度财报不仅是一次经营披露，也构成并购推进过程中的 重要参考窗口 。 # 核心财务表现：收入温和增长，利润端承压明显 从官方披露数据看，本季度豪洛捷呈现出"收入端尚稳、利润端承压"的结构特征： 公司同时披露， 毛利率降至 60.1% ，同比下滑约 150 个基点，其中关税相关成本增加约 1530 万美元， 是导致毛利率承压的重要因素之一。 值得注意的是，在利润下行背景下，公司 经营性现金流达 2.30 亿美元，同比增长超过 20% ，显示其商业 模式仍具备较强的现金生成能力。 收入：3.76 亿美元，同比增长 1.8% 增长主要来自 Endomagnetics 相关产品，反映其在乳腺外科辅助定位领域的持续渗透 季度营收 ：10.5 亿美元，同比增长 2.5% GAAP 净利润 ：1.79 亿美元，同比下降 10.9% GAAP ...

Have you looked into how Hologic (HOLX) performed internationally during the quarter ending December 2025? Considering the widespread global presence of this medical device maker, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understan ...

Key Takeaways Hologic reported Q1 EPS of $1.04 and revenues of $1.05B, missing estimates and pushing shares lower.At Hologic, Diagnostics revenues slipped while GYN Surgical and Skeletal Health delivered strong growth.HOLX saw adjusted gross margin fall 150 bps to 60.1% as higher tariff expenses weighed on results.Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.04 in the first quarter of fiscal 2026, up 1% year over year. The metric missed the Zacks Consensus Estimate by 4.46%. The adj ...

Core Viewpoint - Hologic reported quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share, representing an earnings surprise of -4.46% [1]. Financial Performance - The company posted revenues of $1.05 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 2.14%, compared to $1.02 billion in the same quarter last year [2]. - Over the last four quarters, Hologic has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2]. Stock Performance - Hologic shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 1.9% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.05 billion, and for the current fiscal year, it is $4.51 on revenues of $4.28 billion [7]. - The trend of earnings estimate revisions for Hologic was mixed ahead of the earnings release, which could change following the recent report [6]. Industry Context - The Medical - Instruments industry, to which Hologic belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 27, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HO ...

Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2026 – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – MARLBOROUGH, Mass. (January 29, 2026) – Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights Key fin ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Wall Street analysts expect Hologic (HOLX) to post quarterly earnings of $1.09 per share in its upcoming report, which indicates a year-over-year increase of 5.8%. Revenues are expected to be $1.07 billion, up 4.9% from the year-ago quarter.The current level reflects an upward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's ...

Investment Rating - The report indicates a positive outlook for the private equity (PE) industry, highlighting a resurgence in deal activity and a strong market environment, suggesting a favorable investment rating for the sector in 2025 [8][9]. Core Insights - The private equity sector experienced a significant rebound in 2025, with total deal activity surpassing 9,000 transactions and an aggregate value of approximately $1.2 trillion, marking only the second time in history that deal value exceeded $1 trillion [8][34]. - The second half of 2025 saw a strong recovery in deal flow, compensating for a slowdown in Q2 due to market volatility, with 4,560 deals valued at $632.2 billion [35]. - The report emphasizes the importance of mega-sized transactions, with 150 megadeals totaling $567.8 billion, surpassing previous years and indicating a strong appetite for large-scale investments [9][34]. Summary by Sections Executive Summary - The PE industry rebounded strongly in 2025, achieving a total deal value of $1,155.5 billion, with a year-over-year growth of 36.3% [7]. - Exit activity also saw significant growth, with exit values reaching $728.1 billion, a 90.1% increase from the previous year [7]. Deals - The total number of PE deals in 2025 was 9,019, with a deal count increase of 5.9% year-over-year [7]. - Buyout/LBO transactions accounted for $616.6 billion, reflecting a 57.4% increase compared to 2024 [7]. Fundraising - Fundraising in 2025 was noted as the weakest since 2020, with significant declines in both fund count and capital raised, despite increasing exit activity [12]. - The dry powder in the PE market reached an all-time high of $1.1 trillion, indicating potential for future deal-making [12]. Performance - The report highlights a bifurcation in the market, with large, high-conviction investments performing well, while lower and middle market activities remained muted [72]. - The healthcare sector saw a notable increase in deal value, driven by a few mega-transactions, with a 43.4% rise in total PE-backed healthcare deal value [72]. Valuations - Median global M&A EV/EBITDA multiples reached 10x, recovering from previous lows and indicating a strong valuation environment for PE deals [81]. - PE buyout valuations showed a mixed trend, with EBITDA multiples adjusting down slightly to 12.3x, while revenue multiples increased significantly to 2.5x [82].